Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
| Trades 471 | Longs Won 208/437 47% | Profit Factor 0.8 |
| Profitability | Shorts Won 10/34 29% | Standard Deviation $4,197.74 |
| Average Win $999.18 | Best Trade (Jun 28) $41,074.63 | Sharpe Ratio -91.51 |
| Average Loss -$1,076.07 | Worst Trade (Jul 24) -$36,659.17 | Z-Score -6 (100%) |
| Commissions $0 | Avg. Trade Length 2m 6d | Expectancy -$115.55 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 42 | 38 | 34 | 30 | 25 | 21 | 17 | 13 | 8 | 4 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
RARE Ultragenyx Pharmaceutical Inc. | 3,095.81 | $79,995.84 | $45,576.89 | - | -$34,418.95 | -43.03% | -2.953% |